Description

Based in Denver, Colorado, SeaStar Medical Holding Corporation operates as a medical device company. Its primary mission is to develop innovative therapies and services designed to combat hyperinflammation and cytokine storm, particularly in critically ill individuals. The company specializes in advancing and bringing to market extracorporeal treatments. These therapies are engineered to specifically target the immune "effector cells" that fuel widespread systemic inflammation, which is known to cause direct tissue damage and unleash a cascade of pro-inflammatory cytokines, leading to dysregulated immune responses. SeaStar Medical's product pipeline extends across diverse therapeutic domains. These include both pediatric and adult acute kidney injury, particularly when patients are undergoing continuous renal replacement therapy (CRRT); cardiorenal syndrome observed in cases of congestive heart failure, whether or not an LVAD is present; myocardial stunning associated with end-stage renal disease; and hepatorenal syndrome.